Inhibitors of Platelet Aggregation
The initial inventory of platelet aggregation inhibitors (1) dealt with those isolated from snake venoms. This updated inventory includes in addition to several new inhibitors platelet aggregation from snake venoms, those that were isolated from other animal sources. They are proteins or glycoproteins with their molecular weight ranging from 5000 to several tens of thousands. These factors inhibit platelet aggregation by different mechanisms. A large number of these inhibitors do not exhibit any enzymatic activity. In contrast, some of them exhibit enzymatic activities, such as phospholipase A 2 (PLA 2 ), proteinase and nucleotidase. In general, the mechanism of inhibition of platelet aggregation is well understood for several groups of nonenzymatic proteins. However, further research is required to delineate the mechanism of inhibition by some of the enzymes.
Nonenzymatic inhibitors
Based on the mechanism of inhibition, we have classified the nonenzymatic factors into five classes.
Class I: Antagonists of fibrinogen receptor glycoprotein IIb/IIIa complex (GPIIb/IIIa).
Interaction between fibrinogen and GPIIb/IIIa complex is the important final step to platelet aggregation. Since most platelet agonists go through this final step, these antagonists inhibit platelet aggregation with similar, if not identical, IC 50 values irrespective of the agonist used to initiate aggregation. Several different classes of proteins have been shown to interfere at this critical step. Disintegrins are the most well studied aggregation platelet inhibitors. Although initial studies of purification and characterization of this group of proteins from snake venoms were done in the mid-1980's (2, 3), it was the simultaneous determination of the complete amino acid sequences of echistatin and trigramin (4, 5) that triggered immense research interest in both academia and pharmaceutical industries. These polypeptides contained the RGD tripeptide sequence, the short segment involved in adhesive reactions. Todate more than 40 disulfide-rich polypeptides, known as disintegrins because of their ability to interfere in the integrin activity, have been purified from snake venoms alone (Table 1 ; Figure 1 ). On a molar basis, these polypeptides are 1000 -30,000 times more potent inhibitors of platelet aggregation than the linear RGDS peptide (6) . They are most commonly found in crotalid and viperid snake venoms, but rarely found in elapid and hydrophid snake venoms. Disintegrins are classified into three distinct subfamilies based on their size (7) (Figure 1 ). Short chain disintegrins contain 47-51 amino acid residues and four disulfide bridges; medium chain disintegrins contain 68-75 amino acid residues and six disulfide bridges; and long chain disintegrins contain 83-84 amino acid residues and seven disulfide bridges. Based on the structural analysis of the sequences, we proposed that disintegrins are proteolytic products of longer precursor proteins (8, 9) . Since then cDNA and amino acid sequences of several precursors have been determined (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . These results support the presence of common precursors for metalloproteinases, disintegrins and related proteins. The proteolytic processing to form various subfamilies of disntegrins is most likely be determined by intradomain disulfide bridges and the accessibility of interdomain regions, along with glycosylation (9) .
Disintegrins bind to GPIIb/IIIa on both resting and activated platelets with high affinities (Kd, 10 -7 ~ 10 -8 M) in the presence of divalent cations. Irrespective of their length, they contain the RGD tripeptide sequence in a homologous position and it is described to be essential for their inhibitory properties. Only two disintegrins contain KGD in the homologous position (20, 21) . The authors claim that this makes barbourin (20) a specific inhibitor of interaction between fibrinogen and GPIIa/IIIb and went on to develop several cyclic peptides with KGD sequence as potent inhibitors of platelet aggregation (22) . Three-dimensional structures of four disintegrins have been determined by NMR techniques (23) (24) (25) (26) (27) . The R/KGD segment is located on the tip of a hairpin loop that is stabilized by disulfide bridges. The residues in the immediate neighborhood of this RGD segment appear to contribute significantly to the inhibitory potency of disintegrins (28, 29) .
As mentioned above, there are some venom proteins that contain disintegrin/disintegrin-like domain and these may inhibit platelet aggregation. In some cases, they may also contain metalloproteinase domains that may proteolytically alter the functions of the target protein (see below).
Based on the structure of disintegrins, a variety of cyclic R/KGD peptide or peptide-mimetic derivatives have been developed that are under clinical trials and some of them are found to be effective in reducing ischemic complication, particularly the restenosis after percutaneous transluminal coronary angioplasty (PTCA) (30, 31) . In addition to their role in the development of antithrombotic agents and treatment of cardiovascular diseases, they may also be useful in the treatment of cancer growth and tumor metastasis as well as osteoporosis. Disintegrins have been shown to inhibit the adhesion between tumor cell and extracellular matrices (32) (33) (34) (35) . They also inhibit experimental metastasis of melanoma (36) (37) (38) (39) . Some of them inhibit tumor cell-induced platelet aggregation (40) . Further, disintegrins through the blockade of α v β 3 integrin show potent antiangiogenic effects (41, 42) . Disintegrins block the osteoclast-mediated bone resorption by interfering in the α v β 3 integrin activity (43, 44) and prevent bone loss in mice and rats (45, 46) . Thus the study of disintegrins contributes significantly to both academic and clinical research.
Apart from disintegrins, there are other inhibitors of platelet aggregation, which contain the RGD tripeptide in their structure. These proteins are isolated from snake venom, leeches and ticks (Table 2 ). These polypeptides do not share any significant structural homology with disintegrins ( Figures 2 and 3 ). For example, mambin (or dendroaspin), a platelet aggregation inhibitor isolated from Dendroaspis j. kaimosae snake venom (47) , shows a striking resemblance to the shortchain postsynaptic neurotoxins (48) (Figure 2 ). Although ornatins and decorsin were isolated from leaches, they do not have significant similarity except for RGD containing carboxy terminal segment (49, 50) (Figure 3 ). Variabilin from the salivary glands of hard tick Dermacentor variabilis, despite the presence of RGD, has little homology to any other GPIIb/IIIa antagonists (51).
Disagregin, a potent inhibitor of platelet aggregation isolated from the soft tick Ornithodoros moubata (52) is a GPIIb/IIIa antagonist. Surprisingly, it does not contain the tripeptide RGD ( Figure 2 ). The structure-function relationship of this polypeptide will be of great interest.
Class II: Antagonists of von Willebrand factor receptor glycoprotein Ib (GPIb).
Binding of plasma von Willebrand Factor (vWF) to the platelet glycoprotein, GPIb is assumed to play a key role in the earliest stages of platelet aggregation (53, 54) . So far this group of inhibitors has been purified only from snake venoms (Table 3) . They are heterodimeric with the two subunits (α and β subunits) linked through a disulfide bridge. Only flavocetin-B from Trimeresurus flavoviridis (55) has 3 subunits. All subunits are structurally similar to Ca 2+ -dependent (C-type) lectins. These proteins prevent platelet aggregation by binding to the GPIb and thus blocking the interaction between vWF and its receptors. It has been shown that the GPIb binding site resides on the β-chain subunit (56) . Unlike other inhibitors in this group, echicetin isolated from Echis carinatus also inhibits platelet aggregation induced by α-thrombin (56, 57).
Class III:
Antagonists of collagen-platelet interaction. Subendothelial collagen serves as an anchorage for circulating platelets in the process of hemostasis and thrombosis (58) . Platelets adhere to exposed subendothelial collagen through GPIa/IIa receptors, become activated and the activated platelets aggregate. Some of the platelet aggregation inhibitors interfere with the interaction of collagen with platelet receptors (Table 4) . They have been isolated from snake venoms, leech, soft tick and triatome bug. The inhibitors from snake venoms, similar to disintegrins, are derived from large metalloproteinase/disintegrin precursor proteins. Catrocollastatin-C, atrolysin A/DC and jararhagin-C have the disintegrin-like and cysteine-rich domains (59-61). The former two proteins inhibit platelet aggregation; catrocollastatin-C specifically binds to collagen and inhibits only collagen-induced aggregation, whereas atrolysin A/DC also inhibits ADP-induced aggregation (59, 60) . Their longer counterparts containing a metalloproteinase domain, namely catrocollastatin, atrolysin A and jararhagin, respectively, also inhibit collagen-induced platelet aggregation (60, 62, 63) . Jararhagin, in contrast, binds to GPIa and cleaves GPIIa (64) (see below). Since jararhagin-C has identical sequence to the C-terminal region of jararhagin (61), and since catrocollastatin-C and atrolysin A/DC by themselves inhibit platelet aggregation, it is conceivable that jararhagin-C too acts as a collagen receptor antagonist. A similar situation may also be true in the case of crovidisin (65) . The inhibitors from leech and soft tick bind specifically to collagen fibers and interfere in the interaction between collagen and its receptor GPIa/IIa (66-Class V: Other nonenzymatic inhibitors. These inhibitors in this group inhibit platelet aggregation by currently unknown mechanism(s) ( Table 6 ). Lebetins is a group of inhibitors isolated from Vipera lebetina snake venom (80) . Lebetins 1 are shorter with 12 or 13 residues, whereas lebetins 2 have 37 or 38 residues. Lebetins 1 appear to be derived by proteolysis of their larger counterparts, lebetins 2. It would be interesting to determine whether lebetins, like disintegrins, are proteolytic products of a larger precursor protein. They inhibit platelet aggregation induced by thrombin, collagen and PAF-acether (80) . They also inhibit fibrinogen-induced aggregation of chymotrypsin-treated platelets. Truncation of more than one residue at the amino terminal end results in the loss of activity (81) . These short peptides strongly inhibit collagen-induced thrombocytopenia in rats (80, 81) .
Inhibitors with enzymatic activity
Several proteins with enzymatic activity inhibit platelet aggregation. Some of these enzymes inhibit aggregation by indirect mechanisms either by the formation of a product, which inhibits platelet aggregation or by physical destruction of the agonist or its receptor. In these cases, the mechanisms appear to be simple and are directly dependent on the respective enzymatic activity. The study of such factors may not significantly contribute to our understanding of platelet aggregation.
Nucleotidases. ADP is a potent inducer of platelet aggregation that is secreted from the platelets as dense granules by various agonists. Logically, hydrolysis of ADP should lead to inhibition. Thus ADPases and 5'-nucleotidases inhibit platelet aggregation (Table 7) . Such inhibitors have been isolated from Trimeresurus gramineus (82) , Agkistrodon acutus (83) and Vipera aspis (84) . It was concluded that the removal of ADP and possibly the generation of adenosine was responsible for the inhibitory effect (82).
Phospholipase A 2 enzymes. Some PLA 2 enzymes induce platelet aggregation, whereas others inhibit it. In addition, there are a few PLA 2 enzymes that both initiate as well as inhibit platelet aggregation, though under different conditions. However, not all PLA 2 enzymes affect platelet aggregation. PLA 2 enzymes that affect platelet aggregation are classified into three major classes (85) . Some of the inhibitors (Table 8) inhibit aggregation by mechanism(s) dependent on the enzymatic activity, whereas others appear to inhibit by mechanism(s) that are independent of their phospholipolytic activity. In the former case, the inhibitory effect may be due to the formation of lysophospholipids (86, 87) . However, PLA 2 enzymes from Naja nigricollis (88) , Ophiophagus hannah (89) , Pseudechis papuanus (90) , Agkistrodon acutus (91) and A. halys (92) seem to affect platelet aggregation inhibition by mechanisms independent of their enzymatic activity. The mechanism of antiplatelet effects of this group of PLA 2 enzymes is not yet understood.
Metalloproteinases. Some of the snake venom metalloproteinases inhibit platelet aggregation ( Table 9 ). Most of these were first identified as fibrogenases, since they release peptides from the carboxy-terminal of fibrinogen. They are classified into α and β fibrinogenases based on their specificity for the Aα or Bβ chain of fibrinogen (93) . α-Fibrinogenase inhibits platelet aggregation but not β-fibrinogenase. Since fibrinogen binding to its receptor GPIIb/IIIa complex is the essential final step in the platelet aggregation, it was initially thought that α-fibrinogenase inhibits platelet aggregation as a result of the depletion of fibrinogen or through the generation of plasma fibrinogen degradation products (94) . However, direct testing of fibrinogen degradation products did not show significant inhibition (95) . We showed that an α-fibrogenase from Naja nigricollis (96) inhibits platelet aggregation even in the absence of plasma fibrinogen. This was the first indication that fibrinogen may not be the primary target protein, which determines the antiplatelet effects, for these metalloproteinases. Several other studies also support this possibility. Kistomin, a novel α-fibrinogenase specifically cleaves GPIb resulting in the inhibition of platelet aggregation (97) . Since metalloproteinases exist as large proteins, which are precursors of disintegrins and disintegrin-like polypeptides, these proteins could strongly inhibit platelet aggregation. Disintegrin/disintegrin-like domains in catrocollastatin, atrolysin A and atrolysin E inhibit platelet aggregation (60, 62, 98) . Their precursors containing metalloproteinase domains also inhibit platelet aggregation. In catrocollastatin disintegrin-like domain determines its binding to collagen (62) . Jararhagin, another metalloproteinase containing disintegrin-like domain, binds specifically to GPIa (64) . Both these proteinases specifically inhibit collagen-induced platelet aggregation. Thus non-proteinase domains of metalloproteinases can significantly contribute to the recognition and binding to specific target proteins and hence their antiplatelet effects. The proteolytic activity of the metalloproteinase domain may also play an important role. For example, though jararhagin binds to GPIa, it cleaves the nearby GPIIa (64) . The identification of new target proteins for the metalloproteinases and the structure-function relationships of these antiplatelet proteins could lead to development of novel antithrombotic agents. 
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